30
CARDIOVASCULAR
hamburger
Herculink Elite Rapid Exchange Renal Stent System
Ordering Information
Herculink Elite

Deliverability and reliability.

Excellent strength, visibility, and deliverability to the renal arteries.

Outstanding design

  • Rapid exchange delivery system for single-operator use
  • 6F guide compatibility for all stent diameters (4 mm - 7 mm) and lengths (12 mm, 15 mm, 18 mm)
  • Cobalt chromium multi-link technology that provides strength and excellent visibility
  • Remarkably thin struts with outstanding radial strength

Outstanding performance1

  • 74.3% of patients had a reduction in systolic blood pressure at 3 years
  • 10.5% restenosis at 9 months

Low Restenosis1
Primary Endpoint

10.5% 9-Month Binary Restenosis

Mean SBP Reduced at 1 Month and Remained Low at 3 Years1

Mean SBP Reduced at 1 Month - Remained Low at 3 Years

Excellent Freedom from TLR1

Excellent Freedom from TLR

Reduced Systolic Blood Pressure

74.3% of patients had a reduction in systolic blood pressure at 3 years1

Stent Compliance Label (CE)

Compliance Chart

Data on file at Abbott.

References

  1. Chrysant, George S., et al. Proper Patient Selection Yields Significant and Sustained Reduction in Systolic Blood Pressure Following Renal Artery Stenting in Patients With Uncontrolled Hypertension: Long-Term Results From the HERCULES Trial. The Journal of Clinical Hypertension, 2014 July.

MAT-2115853 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.